Sphingolipids metabolism alteration in the central nervous system: Amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
Ambroxol
Amyotrophic lateral sclerosis
Glucocerebrosidase
Glucosylceramide
Sphingolipids
Therapeutic target
Journal
Seminars in cell & developmental biology
ISSN: 1096-3634
Titre abrégé: Semin Cell Dev Biol
Pays: England
ID NLM: 9607332
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
23
06
2020
revised:
14
10
2020
accepted:
19
10
2020
pubmed:
9
11
2020
medline:
5
1
2022
entrez:
8
11
2020
Statut:
ppublish
Résumé
Sphingolipids are complex lipids. They play a structural role in neurons, but are also involved in regulating cellular communication, and neuronal differentiation and maturation. There is increasing evidence to suggest that dysregulated metabolism of sphingolipids is linked to neurodegenerative processes in amyotrophic lateral sclerosis (ALS), Parkinson's disease and Gaucher's disease. In this review, we provide an overview of the role of sphingolipids in the development and maintenance of the nervous system. We describe the implications of altered metabolism of sphingolipids in the pathophysiology of certain neurodegenerative diseases, with a primary focus on ALS. Finally, we provide an update of potential treatments that could be used to target the metabolism of sphingolipids in neurodegenerative diseases.
Identifiants
pubmed: 33160824
pii: S1084-9521(20)30103-8
doi: 10.1016/j.semcdb.2020.10.008
pii:
doi:
Substances chimiques
Sphingolipids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
82-91Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.